Thiosuccinyl-Crosslinked Hemoglobin Conjugates for Oxygen Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pegylated hemoglobin-based oxygen carriers (HBOCs) have high oxygen affinity, which is not ideal for certain medical indications, and existing pegylation methods alter the oxygen binding properties of hemoglobin, necessitating a technique that maintains oxygen affinity while improving pharmacokinetics and pharmacodynamics.
Innovation Solution
Development of thiosuccinyl-crosslinked hemoglobin conjugates with covalently attached water-soluble polymers, such as PEG, which stabilizes hemoglobin and maintains its oxygen offloading capability without altering the p50 value, allowing for precise therapeutic efficacy in conditions like ischemic/hypoxic injuries and autoimmune diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If pegylation is applied to hemoglobin to improve pharmacokinetics and reduce immunogenicity, then circulation time is prolonged and immunogenicity is reduced, but oxygen affinity is altered and oxygen offloading capability is compromised
Solution Approach 1:
The patent divides the modification process into two independent stages: first crosslinking hemoglobin molecules together using thiosuccinyl groups to form stable polymers, then separately attaching PEG chains to lysine residues on the crosslinked structure. This segmentation allows each modification to be optimized independently without interfering with the other's function
Solution Approach 2:
The thiosuccinyl crosslinking is performed as a preliminary action before PEGylation. By pre-forming the crosslinked hemoglobin structure with controlled oxygen affinity, the subsequent PEG attachment does not alter the already-established oxygen binding properties, thus preserving oxygen offloading capability while still achieving prolonged circulation
2Object-affected harmful factors
If PEG chains are attached to hemoglobin to shield antigenic epitopes, then immunogenicity is reduced, but steric hindrance increases and may impede oxygen binding
Solution Approach 1:
The patent applies PEGylation selectively to exposed lysine residues on the surface of crosslinked hemoglobin molecules, creating localized PEG shields at specific sites. This local modification approach provides immunoprotection where needed while minimizing steric interference with the heme groups and oxygen binding sites that are structurally distinct and protected by the crosslinked framework
Solution Approach 2:
The invention creates a composite structure combining crosslinked hemoglobin polymers with attached PEG chains. The thiosuccinyl crosslinks provide structural integrity and controlled oxygen affinity, while the PEG moieties provide immunoprotection, creating a material where each component contributes its unique properties without compromising the other
3Stability of the object's composition
If crosslinking is used to stabilize hemoglobin structure, then in vivo stability is improved, but oxygen affinity may be altered
Solution Approach 1:
The patent carefully controls the crosslinking parameters by using thiosuccinyl groups that form stable bonds while maintaining the tetrameric structure of hemoglobin. The crosslinking density and pattern are optimized to provide structural stability without distorting the heme pockets or altering the oxygen binding equilibrium, thus achieving enhanced stability with preserved oxygen affinity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The thiosuccinyl-crosslinked hemoglobin conjugates provide improved oxygen delivery and stability, maintaining therapeutic efficacy across various indications without inducing immunogenic responses or renal toxicity, ensuring prolonged circulation and targeted oxygen delivery.
Implementation Method 1
thiosuccinyl crosslinking moiety crosslinks two beta globin chains of the tetrameric hemoglobin
Implementation Method 2
at least one water-soluble polymer covalently attached to the tetrameric hemoglobin
Implementation Method 3
PEG polymer could flip and wrap around the protein surface. This may explain why the conjugates are more resistant to proteolytic degradation, as the access to the susceptible residues is impaired. Similarly, the antigenic determinants are being shielded from exposure
Implementation Method 4
maintains its oxygen offloading capability without altering the p50 value, allowing for precise therapeutic efficacy in conditions like ischemic/hypoxic injuries
Data Source
AI summary
Provided herein are thiosuccinyl-crosslinked hemoglobin conjugates useful as blood replacement agents and therapeutic proteins, pharmaceutical compositions comprising the same and the methods of use and preparation thereof.